NBP — NovaBridge Biosciences
$0.85
+$0.02 (+2.40%)
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Market Cap
$98.59M
Forward P/E
-0.6x
52-Week Range
N/A
NBP Price History
Revenue vs. Net Income
$0
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$20.6M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-40.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
8.8x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
4.2%
CapEx · FY2023
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+18.0%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
